Selected article for: "lung disease and steroid therapy"
Author: Ghous, Ghulam; Shoukat, Hafiz Muhammad Hassan; Tarar, Zahid Ijaz; Zafar, Muhammad Usman
Title: A Review of Interstitial Pneumonitis Caused by Elotuzumab Through Case Discussions and Academic Writings
  • Cord-id: izmyufwh
  • Document date: 2020_10_25
    • ID: izmyufwh
    Snippet: Patients with relapsed or refractory multiple myeloma have undergone two or three previous therapies are now being treated with a humanized IgG1 monoclonal antibody elotuzumab (HuLuc63) that targets F7 signalling lymphocytic activation molecule F7 (SLAMF7)- a signalling lymphocytic activation molecule. It is combined with dexamethasone and lenalidomide/pomalidomide for therapy. Adverse effects associated with elotuzumab consists of peripheral neuropathy, fever, constitutional symptoms (fatigue,
    Document: Patients with relapsed or refractory multiple myeloma have undergone two or three previous therapies are now being treated with a humanized IgG1 monoclonal antibody elotuzumab (HuLuc63) that targets F7 signalling lymphocytic activation molecule F7 (SLAMF7)- a signalling lymphocytic activation molecule. It is combined with dexamethasone and lenalidomide/pomalidomide for therapy. Adverse effects associated with elotuzumab consists of peripheral neuropathy, fever, constitutional symptoms (fatigue, headache, decreased appetite), and infections. A rare side effect of interstitial lung disease has only been observed in a single case. There are two case studies presented below of hypoxic respiratory failure upon this monoclonal antibody treatment both were successfully treated with steroid therapy. This article brings forth the hypothesis that elotuzumab can cause pneumonitis, and discontinuation of elotuzumab along with high-dose corticosteroids helps reverse the pneumonitis.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and acute hypoxic respiratory failure: 1
    • abdominal pain and acute kidney injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
    • abdominal pain and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • abdominal pain and admission day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • abdominal pain and admission fourth day: 1
    • abdominal pain and long history: 1, 2
    • abdominal pain and lung disease: 1, 2, 3, 4, 5, 6, 7
    • abdominal pain and lung injury: 1, 2, 3, 4, 5
    • action mechanism and acute hypoxic respiratory failure: 1
    • action mechanism and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • action mechanism and admission day: 1, 2
    • action mechanism and long history: 1, 2, 3, 4, 5
    • action mechanism and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • action mechanism and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
    • action mechanism and lung toxicity: 1, 2
    • activity relationship and long history: 1, 2
    • activity relationship and lung injury: 1
    • acute hypoxic respiratory failure and admission day: 1, 2, 3, 4, 5
    • acute hypoxic respiratory failure and lung disease: 1, 2, 3, 4, 5